Detection of epidermal growth factor receptor mutations in lung adenocarcinoma cytological specimens by immunocytochemistry
| Autor: | Mayumi Kawashima, Masami Yoshida, Takafumi Ohnishi, Eiichi Morii, Akira Naitoh, Tadasuke Nagatomo |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Cancer Research Pathology medicine.medical_specialty Immunocytochemistry mutation-specific antibody Biology 03 medical and health sciences 0302 clinical medicine immunocytochemistry Biopsy medicine Epidermal growth factor receptor medicine.diagnostic_test Cancer Articles medicine.disease lung adenocarcinoma Molecular medicine 030104 developmental biology Oncology 030220 oncology & carcinogenesis immunohistochemistry Cancer research biology.protein Immunohistochemistry Adenocarcinoma epidermal growth factor receptor A431 cells |
| Zdroj: | Molecular and Clinical Oncology |
| ISSN: | 2049-9450 |
| Popis: | Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR) improve the survival of patients with lung adenocarcinoma, and determine the EGFR mutation status before treatment is necessary. In contrast to biopsy samples, cytological specimens are obtained less invasively and are useful for EGFR mutation analyses. Recently, novel antibodies against two major EGFR mutations were developed: SP111, which is specific for the E746-A750 deletion in exon 19; and SP125, which is specific for the L858R mutation. To the best of our knowledge, no study has evaluated cytological specimens using the two novel antibodies, thus their specificity and sensitivity were examined in surgical resection, and cytological lung adenocarcinoma samples in the present study. Previous screening for EGFR mutation status by molecular testing identified delE746-A750 in 3 cases and the L858R mutation in 7 cases; the other cases did not have the L858R or the delE746-A750 mutation. Using a four-grade scoring system (score 0 to 3+), the immunohistochemistry (IHC) and immunocytochemistry (ICC) results were compared with those of molecular testing. Using a score of ≥2 as positive, IHC and ICC using SP111 demonstrated sensitivities of 100 and 33.3%, and specificities of 100 and 100%, respectively. IHC and ICC using SP125 revealed sensitivities of 100 and 71.4%, and specificities of 100 and 100%, respectively. Therefore, screening for EGFR mutations by ICC may facilitate therapeutic decision-making, particularly in medical centers that are unable to perform molecular testing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|